Advanced Biomed

Cash flows and strategy are unpredictable: the company remains pre‑revenue, recorded a one‑time disposal gain that distorted EPS, and is exiting its core biomedical operations while attempting an AI pivot. Regulatory and jurisdictional risks are high, with historic exposure to PRC/HK and now a renewed Hong Kong focus.

These dynamics make long‑term forecasting highly uncertain.